Patient info

Memantine_hydrochloride_20mg_28 – patient leaflet, side effects, dosage

Updated:
Key facts
Status:
Prescription only (POM)
Medicine strength:
20 mg
Contains active substance:
ATC code:

Patient leaflet - Memantine Hydrochloride 20 mg film-coated tablets

1. What Memantine hydrochloride is and what it is used for

Memantine hydrochloride contains the active substance memantine. It belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D- aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Memantine hydrochloride belongs to a group of medicines called NMDA-receptor antagonists. Memantine hydrochloride acts on these NMDA-receptors improving the transmission of nerve signals and the memory.

Memantine hydrochloride is used for the treatment of patients with moderate to severe Alzheimer’s disease.

2. What you need to know before you

take Memantine hydrochloride Do not take Memantine hydrochloride:

  • if you are allergic to memantine or any of the

    other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or pharmacist before taking Memantine hydrochloride

  • if you have a history of epileptic seizures
  • if you have recently experienced

    a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).

In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine hydrochloride reassessed by your doctor on a regular basis.

If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.

The use of medicinal products called amantadine (for the treatment of Parkinson’s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.

Children and adolescents

Memantine hydrochloride is not recommended for children and adolescents under the age of 18 years.

Other medicines and Memantine hydrochloride

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, Memantine hydrochloride may change the effects of the following medicines and their dose may need to be adjusted by your doctor:

  • amantadine, ketamine, dextromethorphan
  • dantrolene, baclofen
  • cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine
  • hydrochlorothiazide (or any combination with hydrochlorothiazide)
  • anticholinergics (substances generally used to treat movement disorders or intestinal cramps)
  • anticonvulsants (substances used to prevent and relieve seizures)
  • barbiturates (substances generally used to induce sleep)
  • dopaminergic agonists (substances such as

    L-dopa, bromocriptine)

  • neuroleptics (substances used in the treatment of mental disorders)
  • oral anticoagulants

If you go into hospital, let your doctor know that you are taking Memantine hydrochloride. Memantine hydrochloride with food and drink

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy

The use of memantine in pregnant women is not recommended.

Breast-feeding

Women taking Memantine hydrochloride should not breast-feed.

Driving and using machines

Your doctor will tell you whether your illness allows you to drive and to use machines safely. Also, Memantine hydrochloride may change your reactivity, making driving or operating machinery inappropriate.

Memantine hydrochloride contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

11300642 MI-03

Date: Time:

DescriptionMemantine_hydrochloride_20mg_28
LeafletSite Barcode/ DataMatrix2531No. of colours1Page Count2 of 2
4128684Viatris SAP No.400573928
ART-31555-02123152517/0156
41286844
MA No.PLGB 04569/1944United Kingdomwith
Supplier SAP No.N/AN/A
New Supplier Code11300642 MI-033D Render IDN/AMain FontMyriad Pro12 pt
11300642 MI-02195 x 410 mm12 pt
Medis International (Bolatice - CZ)Keyline/Drawing No.195x410

18:00

.
GTIN/PCN/A

Sign-offs

Notes

N/A
N/A
V6 APR 2025

29-AUG-2026

3. How to take Memantine hydrochloride

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Dosage

The recommended dose of Memantine hydrochloride for adults and older people is 20 mg once a day.

In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme. For up-titration other tablet strengths are available.

week 1half a 10 mg tablet
week 2one 10 mg tablet
week 3one and a half 10 mg tablets
week 4 and beyondone 20 mg tablet once a day

The usual starting dose is half a 10 mg tablet once a day (5 mg) for the first week. This is increased to one 10 mg tablet once a day (10 mg) in the second week and to 1 and a half 10 mg tablets once a day in the third week. From the fourth week on, the usual dose is one 20 mg tablet once a day (20 mg). Dosage in patients with impaired kidney function

If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.

Administration

Memantine hydrochloride should be administered orally once a day. To benefit from your medicine you should take it regularly every day at the same time of the day. The tablets should be swallowed with some water. The tablets can be taken with or without food. Duration of treatment

Continue to take Memantine hydrochloride as long as it is of benefit to you. Your doctor should assess your treatment on a regular basis.

If you take more Memantine hydrochloride than you should

  • In general, taking too much Memantine

    hydrochloride should not result in any harm to you. You may experience increased symptoms as described in section 4. “Possible side effects”.

  • If you take a large overdose of Memantine

    hydrochloride, contact your doctor or get medical advice, as you may need medical attention.

If you forget to take Memantine hydrochloride

  • If you find you have forgotten to take your

    dose of Memantine hydrochloride, wait and take your next dose at the usual time.

  • Do not take a double dose to make up for

    a forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. In general, the observed side effects are mild to moderate.

Common (may affect up to 1 in 10 people):

  • Headache, sleepiness, constipation, elevated

    liver function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity Uncommon (may affect up to 1 in 100 people):

  • Tiredness, fungal infections, confusion,

    hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)

    Very rare (may affect up to 1 in 10,000 people):

    • Seizures

Not known (frequency cannot be estimated from the available data):

  • Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions

Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with memantine.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme.

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Memantine hydrochloride

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Memantine hydrochloride contains

  • The active substance is memantine.

    Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.

  • The other ingredients are microcrystalline cellulose, croscarmellose sodium (see section 2 ‘Memantine hydrochloride contains sodium’), magnesium stearate, talc and colloidal anyhdrous silica, all in the tablet core; polydextrose (E1200), hypromellose 3cP (E464), hypromellose 6cP (E464), hypromellose 50cP (E464), iron oxide red (E172), macrogol 400 (E1521), macrogol 8000, all in the tablet coating. What Memantine hydrochloride looks like and contents of the pack

A red film-coated, oval, biconvex, beveled edge tablet marked with “ME” on one side of the tablet and “20” on the other side. Memantine hydrochloride film-coated tablets are available in blister packs of 7, 10, 14, 28, 28 x 1, 30, 42, 50, 56, 56 x 1, 60, 70, 84, 98, 98 x 1, 100, 100 x 1 or 112 film-coated tablets. The pack sizes 28 x 1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in unit dose blisters.

Not all pack sizes may be marketed. Marketing Authorisation Holder

Viatris,

Station Close,

Potters Bar,

EN6 1TL,

United Kingdom.

Manufacturer

Mylan Hungary Kft.

H-2900 Komárom, Mylan utca. 1, Hungary. This leaflet was last revised

in August 2026

4128684

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 04569/1944

Last revision stated in the text: August 2026 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Memantine Hydrochloride 20 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Memantine
Strength 20 mg
Pharmaceutical form Oral tablet
A red film-coated, oval, biconvex, bevelled edge tablet debossed with “ME” on one side of the tablet and “20” on the other side.
How is it taken Oral
Excipients Cellulose, microcrystalline, Croscarmellose sodium, Magnesium stearate, Talc, Silica, colloidal anhydrous, Polydextrose (E1200), Hypromellose 3cP (E464), Hypromellose 6cP (E464), Hypromellose 50cP (E464), Macrogol 400 (E1521), Macrogol 8000 (E1521), Iron oxide red (E172)
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 3 years
Storage This medicinal product does not require any special storage conditions.
Drug group (ATC) Psychoanaleptics, other anti-dementia drugs
  1. N Nervous system drugs
    1. N06 Psychoanaleptics
      1. N06D Anti-dementia drugs
        1. N06DX Other anti-dementia drugs
          1. N06DX01 memantine
Marketing authorisation PLGB 04569/1944 (first authorised 1 January 2021)
Marketing authorisation holder Generics (U.K.) Limited T/A Viatris
Codes GTIN 5016695005461 · BNF 04110000

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.